| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
585,690,000 |
| Market
Cap: |
162.41(B) |
| Last
Volume: |
4,371,869 |
Avg
Vol: |
2,732,650 |
| 52
Week Range: |
$258.59 - $337.38 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NASDAQ BIOTECHNOLOGY |
| |
NASDAQ COMPOSITE |
|
NASDAQ-100 |
| |
S&P 100 |
|
S&P 500 |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 442 |
| Guru Rank Value : 4.5 |
| Guru Occurances : 3 |
|
|
|
|
|
| |
|
Company Profile Amgen is a biotechnology company that focuses on discovering, developing, manufacturing and delivering human therapeutics. Co.'s principal products are Enbrel® (etanercept), Prolia® (denosumab), Otezla® (apremilast), XGEVA® (denosumab), Neulasta® (pegfilgrastim), Aranesp® (darbepoetin alfa), Repatha® (evolocumab), KYPROLIS® (carfilzomib) and Nplate® (romiplostim). Co. also markets a number of other products, including among other, MVASI® (bevacizumab-awwb), Vectibix® (panitumumab), KANJINTI® (trastuzumab-anns), EVENITY® (romosozumab-aqqg), EPOGEN® (epoetin alfa), BLINCYTO® (blinatumomab), AMGEVITA™ (adalimumab), Aimovig® (erenumab-aooe), Parsabiv® (etelcalcetide) and NEUPOGEN® (filgrastim).
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
80,076 |
80,076 |
82,193 |
103,847 |
| Total Sell Value |
$23,789,160 |
$23,789,160 |
$24,451,962 |
$30,260,680 |
| Total People Sold |
6 |
6 |
6 |
6 |
| Total Sell Transactions |
8 |
8 |
9 |
12 |
| End Date |
2025-01-19 |
2024-10-18 |
2024-04-19 |
2023-04-20 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Grygiel Nancy A. |
SVP & CCO |
• • – |
2025-03-17 |
4 |
D |
$313.71 |
$164,384 |
D/D |
(524) |
8,214 |
|
- |
|
| Bradway Robert A |
Chairman, CEO and President |
• • – |
2025-03-17 |
4 |
D |
$313.71 |
$4,032,115 |
D/D |
(12,853) |
587,565 |
|
- |
|
| Khosla Rachna |
SVP, Business Development |
• • – |
2025-03-17 |
4 |
D |
$313.71 |
$153,404 |
D/D |
(489) |
9,340 |
|
- |
|
| Reese David M |
EVP & Chief Technology Officer |
• • – |
2025-03-17 |
4 |
D |
$313.71 |
$1,140,336 |
D/D |
(3,635) |
40,702 |
|
- |
|
| Miller Derek |
SVP, Human Resources |
• • – |
2025-03-17 |
4 |
D |
$313.71 |
$291,750 |
D/D |
(930) |
9,654 |
|
- |
|
| Griffith Peter H. |
EVP & CFO |
• • – |
2025-03-17 |
4 |
D |
$313.71 |
$1,036,812 |
D/D |
(3,305) |
40,334 |
|
- |
|
| Gordon Murdo |
EVP, Global Commercial Ops |
• • – |
2025-03-17 |
4 |
D |
$313.71 |
$1,267,075 |
D/D |
(4,039) |
48,386 |
|
- |
|
| Santos Esteban |
EVP, Operations |
• • – |
2025-03-17 |
4 |
D |
$313.71 |
$1,064,418 |
D/D |
(3,393) |
75,075 |
|
- |
|
| Graham Jonathan P |
EVP & Gen. Counsel & Secy. |
• • – |
2025-03-17 |
4 |
D |
$313.71 |
$988,187 |
D/D |
(3,150) |
32,266 |
|
- |
|
| Busch Matthew C. |
VP, Finance & CAO |
• • – |
2025-03-17 |
4 |
D |
$313.71 |
$54,586 |
D/D |
(174) |
5,117 |
|
- |
|
| Santos Esteban |
EVP, Operations |
• • – |
2025-03-03 |
4 |
A |
$0.00 |
$0 |
D/D |
6,792 |
78,338 |
|
- |
|
| Khosla Rachna |
SVP, Business Development |
• • – |
2025-03-03 |
4 |
A |
$0.00 |
$0 |
D/D |
1,403 |
9,802 |
|
- |
|
| Bradway Robert A |
Chairman, CEO and President |
• • – |
2025-03-03 |
4 |
A |
$0.00 |
$0 |
D/D |
25,734 |
599,925 |
|
- |
|
| Miller Derek |
SVP, Human Resources |
• • – |
2025-03-03 |
4 |
A |
$0.00 |
$0 |
D/D |
2,005 |
10,549 |
|
- |
|
| Griffith Peter H. |
EVP & CFO |
• • – |
2025-03-03 |
4 |
A |
$0.00 |
$0 |
D/D |
7,277 |
43,502 |
|
- |
|
| Reese David M |
EVP & Chief Technology Officer |
• • – |
2025-03-03 |
4 |
A |
$0.00 |
$0 |
D/D |
7,277 |
44,199 |
|
- |
|
| Busch Matthew C. |
VP, Finance & CAO |
• • – |
2025-03-03 |
4 |
A |
$0.00 |
$0 |
D/D |
497 |
5,277 |
|
- |
|
| Gordon Murdo |
EVP, Global Commercial Ops |
• • – |
2025-03-03 |
4 |
A |
$0.00 |
$0 |
D/D |
8,085 |
52,271 |
|
- |
|
| Grygiel Nancy A. |
SVP & CCO |
• • – |
2025-03-03 |
4 |
A |
$0.00 |
$0 |
D/D |
1,503 |
8,713 |
|
- |
|
| Graham Jonathan P |
EVP & Gen. Counsel & Secy. |
• • – |
2025-03-03 |
4 |
A |
$0.00 |
$0 |
D/D |
6,306 |
35,293 |
|
- |
|
| Reese David M |
EVP & Chief Technology Officer |
• • – |
2025-02-21 |
4 |
S |
$304.44 |
$7,679,524 |
D/D |
(25,225) |
36,922 |
|
8% |
|
| Santos Esteban |
EVP, Operations |
• • – |
2025-02-19 |
4 |
S |
$292.84 |
$2,550,903 |
D/D |
(8,711) |
71,546 |
|
6% |
|
| Santos Esteban |
EVP, Operations |
• • – |
2025-02-19 |
4 |
OE |
$156.35 |
$1,361,965 |
D/D |
8,711 |
80,257 |
|
- |
|
| Reese David M |
EVP & Chief Technology Officer |
• • – |
2025-02-19 |
4 |
S |
$293.22 |
$2,554,224 |
D/D |
(8,711) |
62,147 |
|
6% |
|
| Reese David M |
EVP & Chief Technology Officer |
• • – |
2025-02-19 |
4 |
OE |
$156.35 |
$1,361,965 |
D/D |
8,711 |
70,858 |
|
- |
|
911 Records found
|
|
Page 1 of 37 |
|
|
5.35 (1.89%) 
